COVIVIO (COV.PA) Fundamental Analysis & Valuation

EPA:COV • FR0000064578

Current stock price

56.2 EUR
+0.3 (+0.54%)
Last:

This COV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. COV.PA Profitability Analysis

1.1 Basic Checks

  • In the past year COV was profitable.
  • In the past year COV had a positive cash flow from operations.
  • COV had positive earnings in 4 of the past 5 years.
  • COV had a positive operating cash flow in each of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV has a Return On Assets (2.92%) which is comparable to the rest of the industry.
  • The Return On Equity of COV (8.58%) is better than 73.17% of its industry peers.
  • COV has a Return On Invested Capital (3.19%) which is comparable to the rest of the industry.
  • COV had an Average Return On Invested Capital over the past 3 years of 3.14%. This is in line with the industry average of 3.57%.
  • The 3 year average ROIC (3.14%) for COV is below the current ROIC(3.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.92%
ROE 8.58%
ROIC 3.19%
ROA(3y)-0.83%
ROA(5y)0.61%
ROE(3y)-2.81%
ROE(5y)1.64%
ROIC(3y)3.14%
ROIC(5y)2.87%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • COV has a Profit Margin (51.93%) which is in line with its industry peers.
  • COV's Profit Margin has improved in the last couple of years.
  • COV has a Operating Margin of 56.60%. This is in the lower half of the industry: COV underperforms 60.98% of its industry peers.
  • In the last couple of years the Operating Margin of COV has declined.
  • The Gross Margin of COV (71.88%) is comparable to the rest of the industry.
  • COV's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 56.6%
PM (TTM) 51.93%
GM 71.88%
OM growth 3Y-4.77%
OM growth 5Y-2.14%
PM growth 3Y-0.58%
PM growth 5Y7.28%
GM growth 3Y-3.29%
GM growth 5Y-2.55%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. COV.PA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, COV has about the same amount of shares outstanding.
  • COV has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for COV has remained at the same level compared to a year ago.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • Based on the Altman-Z score of 0.60, we must say that COV is in the distress zone and has some risk of bankruptcy.
  • COV has a worse Altman-Z score (0.60) than 75.61% of its industry peers.
  • COV has a debt to FCF ratio of 45.20. This is a negative value and a sign of low solvency as COV would need 45.20 years to pay back of all of its debts.
  • COV has a worse Debt to FCF ratio (45.20) than 70.73% of its industry peers.
  • A Debt/Equity ratio of 1.04 is on the high side and indicates that COV has dependencies on debt financing.
  • COV has a worse Debt to Equity ratio (1.04) than 78.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF 45.2
Altman-Z 0.6
ROIC/WACC0.55
WACC5.78%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.92 indicates that COV may have some problems paying its short term obligations.
  • The Current ratio of COV (0.92) is better than 73.17% of its industry peers.
  • COV has a Quick Ratio of 0.92. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.78, COV is in the better half of the industry, outperforming 65.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.78
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. COV.PA Growth Analysis

3.1 Past

  • COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.26%.
  • COV shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.44% yearly.
  • Looking at the last year, COV shows a quite strong growth in Revenue. The Revenue has grown by 9.31% in the last year.
  • The Revenue has been growing slightly by 7.64% on average over the past years.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)9.31%
Revenue growth 3Y6.59%
Revenue growth 5Y7.64%
Sales Q2Q%40.47%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.56% on average over the next years.
  • COV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.64% yearly.
EPS Next Y3.92%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
EPS Next 5YN/A
Revenue Next Year4.98%
Revenue Next 2Y5.31%
Revenue Next 3Y9.64%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. COV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.83 indicates a reasonable valuation of COV.
  • COV's Price/Earnings ratio is a bit cheaper when compared to the industry. COV is cheaper than 63.41% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. COV is valued rather cheaply when compared to this.
  • COV is valuated reasonably with a Price/Forward Earnings ratio of 11.39.
  • 60.98% of the companies in the same industry are more expensive than COV, based on the Price/Forward Earnings ratio.
  • COV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.36.
Industry RankSector Rank
PE 11.83
Fwd PE 11.39
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • COV's Enterprise Value to EBITDA is on the same level as the industry average.
  • Based on the Price/Free Cash Flow ratio, COV is valued a bit more expensive than the industry average as 73.17% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 26.14
EV/EBITDA 17.28
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)3.02
PEG (5Y)4.84
EPS Next 2Y3.77%
EPS Next 3Y3.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. COV.PA Dividend Analysis

5.1 Amount

  • COV has a Yearly Dividend Yield of 6.67%, which is a nice return.
  • Compared to an average industry Dividend Yield of 5.36, COV pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.80, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.67%

5.2 History

  • The dividend of COV is nicely growing with an annual growth rate of 33.77%!
Dividend Growth(5Y)33.77%
Div Incr Years3
Div Non Decr Years3
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • COV pays out 52.47% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • COV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP52.47%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.PA Fundamentals: All Metrics, Ratios and Statistics

COVIVIO

EPA:COV (4/30/2026, 7:00:00 PM)

56.2

+0.3 (+0.54%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Industry Strength46.62
Industry Growth34.67
Earnings (Last)02-18
Earnings (Next)07-21
Inst Owners40.98%
Inst Owner ChangeN/A
Ins Owners0.41%
Ins Owner ChangeN/A
Market Cap6.27B
Revenue(TTM)1.42B
Net Income(TTM)738.70M
Analysts74.67
Price Target64.07 (14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.67%
Yearly Dividend3.5
Dividend Growth(5Y)33.77%
DP52.47%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.1%
PT rev (3m)1.32%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.56%
EPS NY rev (3m)3.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE 11.83
Fwd PE 11.39
P/S 4.41
P/FCF 26.14
P/OCF 7.65
P/B 0.73
P/tB 0.76
EV/EBITDA 17.28
EPS(TTM)4.75
EY8.45%
EPS(NY)4.94
Fwd EY8.78%
FCF(TTM)2.15
FCFY3.83%
OCF(TTM)7.34
OCFY13.07%
SpS12.74
BVpS77.17
TBVpS74.08
PEG (NY)3.02
PEG (5Y)4.84
Graham Number90.8185 (61.6%)
Profitability
Industry RankSector Rank
ROA 2.92%
ROE 8.58%
ROCE 3.57%
ROIC 3.19%
ROICexc 3.29%
ROICexgc 3.34%
OM 56.6%
PM (TTM) 51.93%
GM 71.88%
FCFM 16.87%
ROA(3y)-0.83%
ROA(5y)0.61%
ROE(3y)-2.81%
ROE(5y)1.64%
ROIC(3y)3.14%
ROIC(5y)2.87%
ROICexc(3y)3.29%
ROICexc(5y)2.99%
ROICexgc(3y)3.34%
ROICexgc(5y)3.02%
ROCE(3y)3.52%
ROCE(5y)3.21%
ROICexgc growth 3Y7.76%
ROICexgc growth 5Y7.65%
ROICexc growth 3Y7.37%
ROICexc growth 5Y7.44%
OM growth 3Y-4.77%
OM growth 5Y-2.14%
PM growth 3Y-0.58%
PM growth 5Y7.28%
GM growth 3Y-3.29%
GM growth 5Y-2.55%
F-Score7
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF 45.2
Debt/EBITDA 9.43
Cap/Depr 402.5%
Cap/Sales 40.75%
Interest Coverage 250
Cash Conversion 86.36%
Profit Quality 32.49%
Current Ratio 0.92
Quick Ratio 0.78
Altman-Z 0.6
F-Score7
WACC5.78%
ROIC/WACC0.55
Cap/Depr(3y)539.5%
Cap/Depr(5y)657.35%
Cap/Sales(3y)47.55%
Cap/Sales(5y)52.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y3.92%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
EPS Next 5YN/A
Revenue 1Y (TTM)9.31%
Revenue growth 3Y6.59%
Revenue growth 5Y7.64%
Sales Q2Q%40.47%
Revenue Next Year4.98%
Revenue Next 2Y5.31%
Revenue Next 3Y9.64%
Revenue Next 5YN/A
EBIT growth 1Y1.09%
EBIT growth 3Y1.5%
EBIT growth 5Y5.33%
EBIT Next Year7.55%
EBIT Next 3Y6.51%
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3Y22.6%
FCF growth 5YN/A
OCF growth 1Y-16.4%
OCF growth 3Y5.5%
OCF growth 5Y10.36%

COVIVIO / COV.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 4 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 4 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


What is the profitability of COV stock?

COVIVIO (COV.PA) has a profitability rating of 5 / 10.


Can you provide the financial health for COV stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


What is the earnings growth outlook for COVIVIO?

The Earnings per Share (EPS) of COVIVIO (COV.PA) is expected to grow by 3.92% in the next year.